Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common stock, $.01 par value per share
-
Shares outstanding
-
46,791,479
-
Total 13F shares
-
53,724,229
-
Share change
-
-2,818,936
-
Total reported value
-
$3,412,895,600
-
Put/Call ratio
-
79%
-
Price per share
-
$63.55
-
Number of holders
-
313
-
Value change
-
-$212,763,194
-
Number of buys
-
173
-
Number of sells
-
146
Institutional Holders of HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) as of Q1 2025
As of 31 Mar 2025,
HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) was held by
313 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,724,229 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, NEUBERGER BERMAN GROUP LLC, WELLINGTON MANAGEMENT GROUP LLP, T. Rowe Price Investment Management, Inc., STATE STREET CORP, Capital Research Global Investors, River Road Asset Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, and ROYCE & ASSOCIATES LP.
This page lists
313
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.